On a reported basis, annual sales rose from KRW 262.5 billion in 2022 to KRW 278.9 billion in 2023 (up 6.3%) and KRW 288.7 billion in 2024 (up 3.5%), then were flat at KRW 288.8 billion in 2025.
Sales have grown for three consecutive years from 2023 through 2025, with 2025 the largest year and 2022 the smallest in the 2022–2025 window. Operating profit rose from KRW 48.2 billion in 2022 to KRW 54.9 billion in 2023 (up 14.0%) and KRW 56.3 billion in 2024 (up 2.4%), making 2024 the largest year.
In 2025, however, operating profit fell 11.9% to KRW 49.6 billion, and the operating margin declined from 19.5% in 2024 to 17.2%.
Net profit attributable to controlling shareholders was KRW 45.3 billion in 2022, KRW 48.3 billion in 2023 (up 6.6%), KRW 32.5 billion in 2024 (down 32.8%), and KRW 38.3 billion in 2025 (up 18.0%). In 2024 operating profit edged higher while controlling-shareholder net profit fell sharply, so the two measures diverged.
Operating cash flow was KRW 63.8 billion in 2022, KRW 49.8 billion in 2023, KRW 26.8 billion in 2024 and KRW 51.1 billion in 2025. The debt-to-equity ratio fell from 23.7% in 2022 to 14.3% in 2025, with total equity of KRW 454.6 billion and total liabilities of KRW 64.9 billion at year-end 2025.
Quarterly sales peaked at KRW 77.2 billion in Q2 2026 before falling 11.9% quarter on quarter to KRW 68.1 billion in Q3 2026, down 8.5% year on year. Q3 2026 operating profit was KRW 2.82 billion, down 77.4% from a year earlier, and the company posted a controlling-shareholder net loss of KRW 7.02 billion.
The company attributes this to an expected recovery charge of about KRW 7.5 billion on a colchicine-free product line deducted from sales, plus foreign exchange losses.
Preliminary January–September 2026 sales were KRW 219.1 billion, up 1.4%, while preliminary cumulative operating profit was KRW 27.4 billion, down 26.1% (announced October 30, 2026). Controlling-shareholder net profit for the last four reported quarters (Q4 2025 to Q3 2026) totaled KRW 55.6 billion.